Christopher K. McLeod

Throughout his career, Christopher has demonstrated expertise in growing companies through strategic collaborations, innovative marketing and new product development.  Christopher is a managing partner at Elm Street Ventures, where he nurtures new ventures as an investor and advisor.

In 2012, Christopher co-founded AxioMx, Inc., serving as president and CEO. AxioMx created technology to quickly develop custom antibodies for use in research and diagnostics. AxioMx was acquired by Abcam, plc in 2015.

Christopher served as president and chief executive officer of 454 Life Sciences from February 2005 through September 2011, where he led the development, manufacturing and marketing of the company’s innovative DNA sequencing products, which were used in research laboratories worldwide. 454 Life Sciences was acquired by Roche Diagnostics in 2007.

Christopher earned his BS magna cum laude with a dual major in economics and engineering and applied science from Yale University and his MS in management from the Sloan School of Management at Massachusetts Institute of Technology.